Gastro-resistant controlled release oral dosage forms
US12048768B2 · kind B2 · utility
0Cited by
10References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 15, 2022 |
| Grant date | Jul 30, 2024 |
| Priority date | — |
| Expiry date | Jun 15, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/454
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to gastro-resistant, controlled release dosage forms comprising Compound (I): or a pharmaceutically acceptable salt and/or solvate thereof, the pharmacokinetic properties of these dosage forms, and the preparation of the same. The novel dosage forms disclosed herein are useful in reducing the risk of QT prolongation in a subject and in treating a disorder in a subject in need thereof, e.g., a subject diagnosed with schizophrenia, for example, in treating the negative symptoms in a subject diagnosed with schizophrenia having the CYP2D6 EM genotype.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.